Abstract
BackgroundAdjuvant temozolomide (TMZ) chemotherapy with standard regimen remarkably improves survival in patients with high-grade glioma (HGG). However, the influence of long-term TMZ chemotherapy on serum ions concentration is unclear.MethodsOne hundred and thirty-eight patients with HGG were included. Their blood samples were collected for blood biochemistry and routine test. The alteration in serum ions concentration, total protein, albumin, globin, and blood cells counts were used to identify the impact of long-term TMZ chemotherapy.ResultsThrough the comparation of quantitative value of diverse parameters among different chemotherapy cycles, we identified that serum potassium concentration had a downward trend after TMZ administration (1st vs. 6th, p < 0.001; 1st vs. 12th, p < 0.001). Additionally, the correlation analysis showed that platelets was negatively correlated with chemotherapy cycles (r = − 0.649, p = 0.023). The hematological adverse events mainly centered on grade 1 to 2.ConclusionLong-term administration of TMZ may lead to serum ions disturbance. Besides the myelosuppression, we should pay attention to the alteration in serum ions concentration, and give patients proper symptomatic treatment when necessary.
Highlights
Adjuvant temozolomide (TMZ) chemotherapy with standard regimen remarkably improves survival in patients with high-grade glioma (HGG)
Some studies reported that LGG could relapse to become HGG and the hypermutation was observed in tumor after receiving TMZ chemotherapy, which promoted the hypothesis of TMZ-induced hypermutation [12, 13]
TMZ chemotherapy could affect the ion channel associated expression profiles To investigate the effect of TMZ chemotherapy on the expression profiles of HGG samples, we downloaded the RNA sequencing data of 73 recurrent HGGs with postoperative chemotherapy information available from China Glioma Genome Atlas (CGGA) database (Table 1)
Summary
Adjuvant temozolomide (TMZ) chemotherapy with standard regimen remarkably improves survival in patients with high-grade glioma (HGG). Median survival of HGG patients remain merely 12–17 months despite of the standard treatment strategy—maximal safe resection with postoperative radiochemotherapy [3, 4]. MGMT promoter methylation was verified to be an independent prognostic factor of glioma patients. High expression level of MGMT was related to the resistance of TMZ and shorter overall survival [9]. Some studies reported that LGG could relapse to become HGG and the hypermutation was observed in tumor after receiving TMZ chemotherapy, which promoted the hypothesis of TMZ-induced hypermutation [12, 13]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
